¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Y52"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
5
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
Y52
Agents primarily affecting the cardiovascular system
ÀÏÂ÷ÀûÀ¸·Î ½ÉÀåÇ÷°ü°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦
Y52.4
Angiotensin-converting-enzyme inhibitors
¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¾à¹°
Y52.6
Antihyperlipidaemic and antiarteriosclerotic drugs
Ç×°íÁöÁúÇ÷Áõ ¹× Ç×µ¿¸Æ°æÈÁõ ¾à¹°
Y52.8
Antivaricose drugs, including sclerosing agents
Ç×Á¤¸Æ·ù¾àÁ¦, °æÈÁ¦ Æ÷ÇÔ
Y52.1
Calcium-channel blockers
Ä®½· ä³Î Â÷´ÜÁ¦
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½